The role of oncomirs in the pathogenesis and treatment of breast cancer

Biomedicine and Pharmacotherapy

Volumn 78, Issue , 2016, Pages 129-139

  Hemmatzadeh, Maryam ^a   Mohammadi, Hamed ^a   Jadidi Niaragh, Farhad ^b   Asghari, Faezeh ^a   Yousefi, Mehdi ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; MicroRNA; OncomiR; Treatment

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MICRORNA; MICRORNA 10B; MICRORNA 155; MICRORNA 21; MICRORNA 22; MICRORNA 222; PEPTIDE NUCLEIC ACID; UNTRANSLATED RNA;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; GENE EXPRESSION; GENE SILENCING; HUMAN; IMMUNOPATHOGENESIS; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; BIOLOGICAL MODEL; BREAST NEOPLASMS; CLASSIFICATION; FEMALE; GENETICS; METABOLISM; ONCOGENE;

BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; ONCOGENES;

EID: 84958640151     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.01.026     Document Type: Review

References (162)

1. Malvezzi M., Bertuccio P., Levi F., La Vecchia C., Negri E. European cancer mortality predictions for the year 2013. Ann. Oncol. 2013, mdt010.
2. DeSantis C., Siegel R., Jemal A. Breast cancer facts and figures 2013-2014. Am. Cancer Soc. 2013, 1-38.
3. Holliday D.L., Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011, 13:215.
4. Serpico D., Molino L., Di Cosimo S. MicroRNAs in breast cancer development and treatment. Cancer Treatment Rev. 2014, 40:595-604.
5. Shatseva T., Lee D.Y., Deng Z., Yang B.B. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J. Cell Sci. 2011, 124:2826-2836.
6. Viticchiè G., Lena A.M., Latina A., Formosa A., Gregersen L.H., Lund A.H., et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011, 10:1121-1131.
7. Yu B., Zhou S., Wang Y., Qian T., Ding G., Ding F., et al. MiR-221 and miR-222 promote Schwann cell proliferation and migration by targeting LASS2 after sciatic nerve injury. J. Cell Sci. 2012, 125:2675-2683.
8. Lerner M., Lundgren J., Akhoondi S., Jahn A., Ng H.-F., Moqadam F.A., et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle 2011, 10:2172-2183.
9. Liang L.-h. Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy. Acta Pharmacol. Sin. 2011, 32:1311-1320.
10. Pernaute B., Spruce T., Rodriguez T.A., Manzanares M. MiRNA-mediated regulation of cell signaling and homeostasis in the early mouse embryo. Cell Cycle 2011, 10:584-591.
11. Du W.W., Yang B.B., Yang B.L., Deng Z., Fang L., Shan S.W., et al. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One 2011, 6:e26396.
12. Fang L., Du W.W., Yang W., Rutnam Z.J., Peng C., Li H., et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012, 11:4352-4365.
13. Luo L., Ye G., Nadeem L., Fu G., Yang B.B., Honarparvar E., et al. MicroRNA-378a-5p promotes trophoblast cell survival, migration and invasion by targeting Nodal. J. Cell Sci. 2012, 125:3124-3132.
14. Siragam V., Rutnam Z.J., Yang W., Fang L., Luo L., Yang X., et al. MicroRNA miR-98 inhibits tumor angiogenesis and invasion by targeting activin receptor-like kinase-and matrix metalloproteinase-11. Oncotarget 2012, 3:1370-1385.
15. Du W.W., Fang L., Li M., Yang X., Liang Y., Peng C., et al. MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling. J. Cell Sci. 2013, 126:1440-1453.
16. Kahai S., Lee S.-C., Lee D.Y., Yang J., Li M., Wang C.-H., et al. MicroRNA miR-378 regulates nephronectin expression modulating osteoblast differentiation by targeting GalNT-7. PLoS One 2009, 4:e7535.
17. Rutnam Z.J., Yang B.B. The non-coding 3' UTR of CD44 induces metastasis by regulating extracellular matrix functions. J. Cell Sci. 2012, 125:2075-2085.
18. Wang C.-H., Lee D.Y., Deng Z., Jeyapalan Z., Lee S.-C., Kahai S., et al. MicroRNA miR-328 regulates zonation morphogenesis by targeting CD44 expression. PLoS One 2008, 3. e2420-e2420.
19. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
20. Bhaskaran M., Mohan M. MicroRNAs history, biogenesis, and their evolving role in animal development and disease. Vet. Pathol. Online 2014, 51:759-774.
21. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
22. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-mediates temporal pattern formation in C. elegans. Cell 1993, 75:855-862.
23. Reinhart B.J., Slack F.J., Basson M., Pasquinelli A.E., Bettinger J.C., Rougvie A.E., et al. The 21-nucleotide let-RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901-906.
24. Slack F.J., Basson M., Liu Z., Ambros V., Horvitz H.R., Ruvkun G. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-regulatory RNA and the LIN-29 transcription factor. Mol. cell 2000, 5:659-669.
25. Pasquinelli A.E., Reinhart B.J., Slack F., Martindale M.Q., Kuroda M.I., Maller B., et al. Conservation of the sequence and temporal expression of let-heterochronic regulatory RNA. Nature 2000, 408:86-89.
26. D.P Bartel MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
27. Rutnam Z.J., Wight T.N., Yang B.B. miRNAs regulate expression and function of extracellular matrix molecules. Matrix Biol. 2013, 32:74-85.
28. Lagos-Quintana M., Rauhut R., Meyer J., Borkhardt A., Tuschl T. New microRNAs from mouse and human. Rna 2003, 9:175-179.
29. Lee Y., Jeon K., Lee J.T., Kim S., Kim V.N. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. 2002, 21:4663-4670.
30. Hutvágner G., McLachlan J., Pasquinelli A.E., Bálint É., Tuschl T., Zamore P.D. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-small temporal RNA. Science 2001, 293:834-838.
31. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425:415-419.
32. Wu H., Xu H., Miraglia L.J., Crooke S.T. Human RNase III is a 160-kDa protein involved in preribosomal RNA processing. J. Biol. Chem. 2000, 275:36957-36965.
33. Denli A.M., Tops B.B., Plasterk R.H., Ketting R.F., Hannon G.J. Processing of primary microRNAs by the Microprocessor complex. Nature 2004, 432:231-235.
34. Gregory R.I., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., et al. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432:235-240.
35. Han J., Lee Y., Yeom K.-H., Kim Y.-K., Jin H., Kim V.N. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004, 18:3016-3027.
36. Landthaler M., Yalcin A., Tuschl T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr. Biol. 2004, 14:2162-2167.
37. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003, 17:3011-3016.
38. Lund E., Güttinger S., Calado A., Dahlberg J.E., Kutay U. Nuclear export of microRNA precursors. Science 2004, 303:95-98.
39. Lee Y., Hur I., Park S.Y., Kim Y.K., Suh M.R., Kim V.N. The role of PACT in the RNA silencing pathway. EMBO J. 2006, 25:522-532.
40. Bernstein E., Caudy A.A., Hammond S.M., Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001, 409:363-366.
41. Schwarz D.S., Hutvágner G., Du T., Xu Z., Aronin N., Zamore P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
42. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294:853-858.
43. Jiang Q., Wang Y., Hao Y., Juan L., Teng M., Zhang X., et al. MiR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res. 2009, 37:D98-D104.
44. Sun K., Wang W., Zeng J.-j., Wu C.-t., Lei S.-t., Li G.-x. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol. Sin. 2011, 32:375-384.
45. Li B. A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma. Acta Pharmacol. Sin. 2012, 33:3-4.
46. Yang S., Li Y. MicroRNAs: novel factors in clinical diagnosis and prognosis for nasopharyngeal carcinoma. Acta Pharmacol. Sin. 2012, 33:981-982.
47. Rutnam Z.J., Yang B.B. The involvement of microRNAs in malignant transformation. Histol. Histopathol. 2012, 27:1263-1270.
48. Kasinski A.L., Slack F.J. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 2011, 11:849-864.
49. Wang S., Bian C., Yang Z., Bo Y., Li J., Zeng L., et al. MiR-145 inhibits breast cancer cell growth through RTKN. Int. J. Oncol. 2009, 34:1461-1466.
50. Cheng C.J., Slack F.J. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J. (Sudbury, Mass). 2012, 18:232.
51. Wang D., Qiu C., Zhang H., Wang J., Cui Q., Yin Y. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010, 5:e13067.
52. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., et al. A microRNA polycistron as a potential human oncogene. Nature 2005, 435:828-833.
53. Dahiya N., Sherman-Baust C.A., Wang T.-L., Davidson B., Shih Ie M., Zhang Y., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PloS One 2008, 3:e2436.
54. Starczynowski D.T., Kuchenbauer F., Wegrzyn J., Rouhi A., Petriv O., Hansen C.L., et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp. Hematol. 2011, 39:167-178. e164.
55. Garzon R., Heaphy C.E., Havelange V., Fabbri M., Volinia S., Tsao T., et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009, 114:5331-5341.
56. Zhao J.-J., Lin J., Lwin T., Yang H., Guo J., Kong W., et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010, 115:2630-2639.
57. Santanam U., Zanesi N., Efanov A., Costinean S., Palamarchuk A., Hagan J.P., et al. Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. Proc. Natl. Acad. Sci. 2010, 107:12210-12215.
58. Gironella M., Seux M., Xie M.-J., Cano C., Tomasini R., Gommeaux J., et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc. Natl. Acad. Sci. 2007, 104:16170-16175.
59. Asangani I., Rasheed S., Nikolova D., Leupold J., Colburn N., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136.
60. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl Acad. Sci U. S. A. 2005, 102:13944-13949.
61. Akao Y., Nakagawa Y., Naoe T. Let-microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 2006, 29:903-906.
62. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6:857-866.
63. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2999-3004.
64. Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., et al. MiR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 2007, 282:23716-23724.
65. Sun T., Wang Q., Balk S., Brown M., Lee G.-S.M., Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009, 69:3356-3363.
66. Ribas J., Ni X., Haffner M., Wentzel E.A., Salmasi A.H., Chowdhury W.H., et al. MiR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69:7165-7169.
67. Dyrskjøt L., Ostenfeld M.S., Bramsen J.B., Silahtaroglu A.N., Lamy P., Ramanathan R., et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009, 69:4851-4860.
68. Liu W., Zabirnyk O., Wang H., Shiao Y., Nickerson M., Khalil S., et al. MiR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene 2010, 29:4914-4924.
69. Ueda T., Volinia S., Okumura H., Shimizu M., Taccioli C., Rossi S., et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11:136-146.
70. Chen X., Chen S., Xiu Y.-L., Sun K.-X., Zong Z.-H., Zhao Y. RhoC is a major target of microRNA-93-P in epithelial ovarian carcinoma tumorigenesis and progression. Mol. Cancer 2015, 14:31.
71. Liang H., Yan X., Pan Y., Wang Y., Wang N., Li L., et al. MicroRNA-223 delivered by platelet-derived microvesicles promotes lung cancer cell invasion via targeting tumor suppressor EPB41L3. Mol. Cancer 2015, 14:58.
72. Zhang Z., Zhang Y., Sun X.-X., Ma X., Chen Z.-N. MicroRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma. Mol. Cancer 2015, 14:1-15.
73. Majid S., Dar A.A., Saini S., Yamamura S., Hirata H., Tanaka Y., et al. MicroRNA-205-directed transcriptional activation of tumor suppressor genes in prostate cancer. Cancer 2010, 116:5637-5649.
74. Kenney P.A., Wszolek M.F., Rieger-Christ K.M., Neto B.S., Gould J.J., Harty N.J., et al. Novel ZEB1 expression in bladder tumorigenesis. BJU Int. 2011, 107:656-663.
75. Catto J.W., Alcaraz A., Bjartell A.S., White R.D.V., Evans C.P., Fussel S., et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur. Urol. 2011, 59:671-681.
76. Mayr C., Hemann M.T., Bartel D.P. Disrupting the pairing between let-and Hmga2 enhances oncogenic transformation. Science 2007, 315:1576-1579.
77. Fabian M.R., Sonenberg N. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat. Struct. Mol. Biol. 2012, 19:586-593.
78. Hassan O., Ahmad A., Sethi S., Sarkar F.H. Recent updates on the role of microRNAs in prostate cancer. J. Hematol. Oncol. 2012, 5:13.
79. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol. 2012, 13:e249-e258.
80. Tang J., Ahmad A., Sarkar F.H. The role of microRNAs in breast cancer migration, invasion and metastasis. Int. J. Mol. Sci. 2012, 13:13414-13437.
81. Lal E.O.D.A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010, 12:201.
82. Ma L., Young J., Prabhala H., Pan E., Mestdagh P., Muth D., et al. MiR-a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12:247-256.
83. Chen D., Sun Y., Wei Y., Zhang P., Rezaeian A.H., Teruya-Feldstein J., et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 2012, 18:1511-1517.
84. Ma L., Reinhardt F., Pan E., Soutschek J., Bhat B., Marcusson E.G., et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28:341-347.
85. Hossain A., Kuo M.T., Saunders G.F. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol. Cell. Biol. 2006, 26:8191-8201.
86. Si M., Zhu S., Wu H., Lu Z., Wu F., Mo Y. MiR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
87. Luthra R., Singh R., Luthra M., Li Y., Hannah C., Romans A., et al. MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 2008, 27:6667-6678.
88. Kong W., Yang H., Zhao J.-j., Coppola D., Dalton W.S., et al. MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28:6773-6784.
89. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
90. Iorio M.V., Ferracin M., Liu C.-G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65:7065-7070.
91. Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., et al. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res. 2009, 69:2195-2200.
92. Li L., Yuan L., Luo J., Gao J., Guo J., Xie X. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-and SIRT1. Clin. Exp. Med. 2013, 13:109-117.
93. Reddy S.D.N., Ohshiro K., Rayala S.K., Kumar R. MicroRNA-a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res. 2008, 68:8195-8200.
94. Cochrane D.R., Howe E.N., Spoelstra N.S., Richer J.K. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J. Oncol. 2009, 2010.
95. Uhlmann S., Zhang J., Schwäger A., Mannsperger H., Riazalhosseini Y., Burmester S., et al. miR-200bc/429 cluster targets PLCγ1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene 2010, 29:4297-4306.
96. Cheng C.-W., Wang H.-W., Chang C.-W., Chu H.-W., Chen C.-Y., Yu J.-C., et al. MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast cancer Res. Treat. 2012, 134:1081-1093.
97. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. Let-regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
98. Selcuklu S.D., Donoghue M.A., Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem. Soc. Trans. 2009, 37:918.
99. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
100. Chan J.A., Krichevsky A.M., Kosik K.S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005, 65:6029-6033.
101. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
102. Volinia S., Calin G.A., Liu C.-G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
103. Slaby O., Svoboda M., Fabian P., Smerdova T., Knoflickova D., Bednarikova M., et al. Altered expression of miR-21 miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007, 72:397-402.
104. Sempere L.F., Christensen M., Silahtaroglu A., Bak M., Heath C.V., Schwartz G., et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007, 67:11612-11620.
105. Yan L.-X., Huang X.-F., Shao Q., Huang M.-Y., Deng L., Wu Q.-L., et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
106. Zhu S., Si M.-L., Wu H., Mo Y.-Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol.Chem. 2007, 282:14328-14336.
107. Zhu S., Wu H., Wu F., Nie D., Sheng S., Mo Y.-Y. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008, 18:350-359.
108. Adams B.D., Furneaux H., White B.A. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines. Mol. Endocrinol. 2007, 21:1132-1147.
109. Fujita S., Ito T., Mizutani T., Minoguchi S., Yamamichi N., Sakurai K., et al. MiR-21 gene expression triggered by AP-is sustained through a double-negative feedback mechanism. J. Mol. Biol. 2008, 378:492-504.
110. Qian B., Katsaros D., Lu L., Preti M., Durando A., Arisio R., et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res. Treat. 2009, 117:131-140.
111. Mattiske S., Suetani R.J., Neilsen P.M., Callen D.F. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2012, 21:1236-1243.
112. Chen J., Wang B.C., Tang J.H. Clinical significance of MicoRNA-155 expression in human breast cancer. J. Surg. Oncol. 2012, 106:260-266.
113. Czyzyk-Krzeska M., Zhang X. MiR-155 at the heart of oncogenic pathways. Oncogene 2014, 33:677-678.
114. Jiang S., Zhang H.-W., Lu M.-H., He X.-H., Li Y., Gu H., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70:3119-3127.
115. Kong W., He L., Coppola M., Guo J., Esposito N.N., Coppola D., et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 2010, 285:17869-17879.
116. Bracken C., Gregory P., Khew-Goodall Y., Goodall G. The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell. Mol. Life Sci. 2009, 66:1682-1699.
117. Chang S., Wang R.-H., Akagi K., Kim K.-A., Martin B.K., Cavallone L., et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011, 17:1275-1282.
118. Sasayama T., Nishihara M., Kondoh T., Hosoda K., Kohmura E. MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int. J. Cancer 2009, 125:1407-1413.
119. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
120. Ma L. Role of miR-10b in breast cancer metastasis. Breast Cancer Res. 2010, 12:210.
121. Yang J., Mani S.A., Weinberg R.A. Exploring a new twist on tumor metastasis. Cancer Res. 2006, 66:4549-4552.
122. Edmonds M.D., Hurst D.R., Vaidya K.S., Stafford L.J., Chen D., Welch D.R. Breast cancer metastasis suppressor 1 coordinately regulates metastasis-associated microRNA expression. Int. J. Cancer 2009, 125:1778-1785.
123. Stinson S., Lackner M.R., Adai A.T., Yu N., Kim H.-J., O'Brien C., et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci. Signaling 2011, 4. ra41-ra41.
124. Shah M.Y., Calin G.A. MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. Genome Med. 2011, 3:56.
125. Stinson S., Lackner M.R., Adai A.T., Yu N., Kim H.-J., O'Brien C., et al. MiR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci. Signaling 2011, 4. pt5-pt5.
126. Guttilla I., Phoenix K., Hong X., Tirnauer J., Claffey K., White B. Prolonged mammosphere culture of MCF-cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res. Treat. 2012, 132:75-85.
127. Lambertini E., Lolli A., Vezzali F., Penolazzi L., Gambari R., Piva R. Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. BMC Cancer 2012, 12:445.
128. Piva R., Spandidos D.A., Gambari R. From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (review). Int. J. Oncol. 2013, 43:985-994.
129. Zhao J.-J., Lin J., Yang H., Kong W., He L., Ma X., et al. MicroRNA-221/222 negatively regulates estrogen receptorα and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.
130. Andorfer C.A., Necela B.M., Thompson E.A., Perez E.A. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol. Med. 2011, 17:313-319.
131. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
132. Lowery A.J., Miller N., Devaney A., McNeill R.E., Davoren P.A., Lemetre C., et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009, 11:R27.
133. Mattie M.D., Benz C.C., Bowers J., Sensinger K., Wong L., Scott G.K., et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer 2006, 5:24.
134. Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2010, 251:499-505.
135. Wu X., Somlo G., Yu Y., Palomares M.R., Li A.X., Zhou W., et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J. Transl. Med. 2012, 10. 10.1186.
136. Lowery A.J., Miller N., McNeill R.E., Kerin M.J. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin. Cancer Res. 2008, 14:360-365.
137. Jeon H.-M., Sohn Y.-W., Oh S.-Y., Kim S.-H., Beck S., Kim S., et al. ID4 Imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Cancer Res. 2011, 71:3410-3421.
138. Dehghanzadeh R., Jadidi-Niaragh F., Gharibi T., Yousefi M. MicroRNA-induced drug resistance in gastric cancer. Biomed. Pharm. 2015, 74:191-199.
139. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharm. 2010, 79:817-824.
140. Kovalchuk O., Filkowski J., Meservy J., Ilnytskyy Y., Tryndyak V.P., Vasyl'F C., et al. Involvement of microRNA-451 in resistance of the MCF-breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther. 2008, 7:2152-2159.
141. Sehdev S., Martin G., Sideris L., Lam W., Brisson S. Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr. Oncol. 2009, 16.
142. Miller T.E., Ghoshal K., Ramaswamy B., Roy S., Datta J., Shapiro C.L., et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 2008, 283:29897-29903.
143. Serrano-Olvera A., Dueñas-González A., Gallardo-Rincón D., Candelaria M., De la Garza-Salazar J. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. Cancer Treat. Rev. 2006, 32:180-190.
144. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 2007.
145. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353:1673-1684.
146. Bedard P.L., de Azambuja E., Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-therapy in breast cancer. Curr. Cancer Drug Targets 2009, 9:148-162.
147. Eichhorn P.J., Baselga J. HER2 signatures in breast cancer: ready to go to print?. J. Clin. Oncol. 2010, 28:1809-1810.
148. Gong C., Yao Y., Wang Y., Liu B., Wu W., Chen J., et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem. 2011, 286:19127-19137.
149. Huang T.-H., Wu F., Loeb G.B., Hsu R., Heidersbach A., Brincat A., et al. Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J. Biol. Chem. 2009, 284:18515-18524.
150. Nagata Y., Lan K.-H., Zhou X., Tan M., Esteva F.J., Sahin A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
151. C.S., Velu, H.L., Grimes, 2012. Utilizing antagomiR (antisense microRNA) to knock down microRNA in murine bone marrow cells, Rational Drug Design, Springer, 185-195.
152. Poltronieri P., D'Urso P.I., Mezzolla V., D'Urso O.F. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Chem. Biol. Drug Des. 2013, 81:79-84.
153. Kota J., Chivukula R.R., O'Donnell K.A., Wentzel E.A., Montgomery C.L., Hwang H.-W., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137:1005-1017.
154. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10:704-714.
155. Bahrami B., Mohammadnia-Afrouzi M., Bakhshaei P., Yazdani Y., Ghalamfarsa G., Yousefi M., et al. Folate-conjugated nanoparticles as a potent therapeutic approach in targeted cancer therapy. Tumor Biol. 2015, 36:5727-5742.
156. Hosseini M., Haji-Fatahaliha M., Jadidi-Niaragh F., Majidi J., Yousefi M. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy. Artif. Cells Nanomed. Biotechnol. 2015, 1-11.
157. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
158. Karkare S., Bhatnagar D. Promising nucleic acid analogs and mimics: characteristic features and applications of PNA, LNA, and morpholino. Appl. Microbiol. Biotechnol. 2006, 71:575-586.
159. Demidov V.V., Frank-Kamenetskii M.D. Sequence-specific targeting of duplex DNA by peptide nucleic acids via triplex strand invasion. Methods 2001, 23:108-122.
160. Sforza S., Tedeschi T., Calabretta A., Corradini R., Camerin C., Tonelli R., et al. A peptide nucleic acid embedding a pseudopeptide nuclear localization sequence in the backbone behaves as a peptide mimic. Eur. J. Org. Chem. 2010, 2010:2441-2444.
161. Brognara E., Fabbri E., Aimi F., Manicardi A., Bianchi N., Finotti A., et al. Peptide nucleic acids targeting miR-221 modulate p27Kip1 expression in breast cancer MDA-MB-231 cells. Int. J. Oncol. 2012, 41:2119-2127.
162. Yan L.X., Wu Q.N., Zhang Y., Li Y.Y., Liao D.Z., Hou J.H., et al. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 2011, 13:R2.